Sangamo Therapeutics Inc (NASDAQ:SGMO)
| 9.57 Delayed Data As of Jul 30 |  -0.14 / -1.44%Today’s Change | 9.05 Today|||52-Week Range 19.43 | -38.67% Year-to-Date |
Latest SGMO News | Press Releases
| Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline Jul 28 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 9.72 |
| Today’s open | 9.73 |
| Day’s range | 9.54 - 9.95 |
| Volume | 621,319 |
| Average volume (3 months) | 1,015,495 |
| Market cap | $1.4B |
Data as of 4:00pm ET, 07/30/2021
Growth & Valuation
| Earnings growth (last year) | -6.00% |
| Earnings growth (this year) | -41.36% |
| Earnings growth (next 5 years) | -2.33% |
| Revenue growth (last year) | +15.39% |
| P/E ratio | NM |
| Price/Sales | 17.75 |
| Price/Book | 2.73 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RGNXRegenxbio Inc | -0.23 | -0.71% |
| QUREUniqure NV | -0.15 | -0.51% |
| OCGNOcugen Inc | -0.11 | -1.61% |
| HRTXHeron Therapeutics I... | +0.04 | +0.32% |
Data as of 4:34pm ET, 07/30/2021
Financials
| Next reporting date | August 6, 2021 |
| EPS forecast (this quarter) | -$0.31 |
| Annual revenue (last year) | $118.2M |
| Annual profit (last year) | -$121.0M |
| Net profit margin | -102.37% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Brisbane, California |
Forecasts
